Merck Stock Hits Near High After Q2 Earnings Beat
Merck & Co., Inc.'s stock remains near its 52-week high of $135.05, closing at $133.085 on August 12, 2026, after reporting a strong second-quarter performance.
The company's revenue reached $16.61 billion, beating the estimated $16.37 billion and showing a 5.1% increase from last year.
Adjusted earnings of $2.76 per share also surpassed expectations, as analysts had predicted $2.60. The forecast for full-year earnings per share (EPS) was revised to $2.75, which is within Merck's own guidance range of $2.66 to $2.76.
The growth in revenue can be attributed to the success of Keytruda and other oncology launches, as well as animal health products. The expansion of ENFLONSIA's label for RSV prevention has also contributed to the company's pipeline momentum.